Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer

BACKGROUND: There is a high unmet need for effective treatments for patients with squamous non-small cell lung cancer (NSCLC). Eli Lilly and Company is conducting a phase III, randomized, multicenter, open-label study of gemcitabine plus cisplatin plus necitumumab (GC + N) versus gemcitabine plus ci...

Descripción completa

Detalles Bibliográficos
Autores principales: DeLozier, Amy M, Brown, Jacqueline, Natanegara, Fanni, Zhao, Luping, Cui, Zhanglin Lin, Able, Stephen L, Bowman, Lee, Treat, Joseph, Hess, Lisa M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169645/
https://www.ncbi.nlm.nih.gov/pubmed/25227571
http://dx.doi.org/10.1186/2046-4053-3-102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169645/
https://www.ncbi.nlm.nih.gov/pubmed/25227571
http://dx.doi.org/10.1186/2046-4053-3-102

Ejemplares similares